<p>富兰克林资源公司在最近向证券交易委员会提交的 13F 文件中披露，在第四季度其在 Olema Pharmaceuticals, Inc.（纳斯达克代码：OLMA - 免费报告）的股份增加了 1,714.9%。该基金在季度内购买了 258,625 股后，持有 273,706 股公司的股票。富兰克林资源公司在最近一个季度末持有 Olema Pharmaceuticals 约 0.48% 的股份，价值 1,596,000 美元。</p>
<p>获取 <strong>Olema Pharmaceuticals</strong> 警报：</p>
<p>其他一些机构投资者和对冲基金最近也对 OLMA 的持仓进行了调整。威灵顿管理集团在第四季度将其在 Olema Pharmaceuticals 的股份提高了 52.1%。威灵顿管理集团现在拥有 1,525,484 股公司的股票，价值 8,839,000 美元，在此期间又购买了 522,799 股。施罗德投资管理集团在第四季度将其在 Olema Pharmaceuticals 的股份增加了 548.7%。施罗德投资管理集团现在拥有 533,111 股公司的股票，价值 2,991,000 美元，在上个季度又购买了 450,924 股。Pier Capital LLC 在第四季度购买了 Olema Pharmaceuticals 的新股份，价值约 1,588,000 美元。Pictet 资产管理控股公司在第四季度将其在 Olema Pharmaceuticals 的股份提高了 12.9%。Pictet 资产管理控股公司现在拥有 1,883,354 股公司的股票，价值 10,980,000 美元，在上个季度又收购了 215,895 股。最后，摩根大通在第三季度将其在 Olema Pharmaceuticals 的持股增加了 658.7%。摩根大通现在拥有 181,032 股公司的股票，价值 2,162,000 美元，在此期间又收购了 157,171 股。机构投资者持有公司 91.78% 的股份。</p>
<h2>Olema Pharmaceuticals 股票上涨 7.7%</h2>
<p>周二，OLMA 股票开盘价为 4.06 美元。该公司的 50 日移动平均价为 4.30 美元，200 日移动平均价为 7.21 美元。公司市值为 2.7743 亿美元，市盈率为-1.85，贝塔值为 2.10。Olema Pharmaceuticals, Inc.的 52 周最低价为 2.86 美元，最高价为 16.62 美元。</p>
<p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）最近于 3 月 18 日（星期二）发布了季度财报。公司报告季度每股收益为（0.51 美元），超出市场共识预期的（0.63 美元）0.12 美元。分析师预计 Olema Pharmaceuticals, Inc.在本年度的每股收益将为-2.33 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师对该股票发表了看法。HC Wainwright 在 3 月 19 日（星期三）的研究报告中重申了对 Olema Pharmaceuticals 的 “买入” 评级，并设定了 30.00 美元的目标价。摩根大通在 3 月 28 日（星期五）的研究报告中将 Olema Pharmaceuticals 的目标价从 30.00 美元下调至 28.00 美元，并对该公司设定了 “增持” 评级。最后，Oppenheimer 在 3 月 19 日（星期三）的研究报告中重申了 “跑赢大盘” 评级，并将 Olema Pharmaceuticals 的目标价设定为 25.00 美元（低于 30.00 美元）。</p>
<p><strong>阅读我们对 OLMA 的最新分析</strong></p>
<h2>Olema Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症治疗的发现、开发和商业化。其主要产品候选药物为 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的第三阶段临床试验；同时 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的 1/2 期临床试验，并开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过 Olema Pharmaceuticals</li>
<li>3 只沃伦·巴菲特在波动时期必须购买的股票</li>
<li>尽管华尔街下调评级，为什么 NVIDIA 股票可能会飙升</li>
<li>万亿美元市值的意义超越数字</li>
<li>第一季度内部人士购买的三只大型股票：买入、卖出或持有</li>
<li>便士股票适合你的投资组合吗？</li>
<li>3 只热销新 IPO 逆势而上，抵御 2025 年市场下滑</li>
</ul>
<p><strong>想看看其他对冲基金持有的 OLMA 吗？</strong> 访问 HoldingsChannel.com 获取 Olema Pharmaceuticals, Inc.（纳斯达克代码：OLMA - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Olema Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前...而 Olema Pharmaceuticals 并不在名单上。</p>
<p>虽然 Olema Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OLMA

富兰克林资源

<p>富兰克林资源公司在最近向证券交易委员会提交的 13F 文件中表示，在第四季度其在 Olema Pharmaceuticals, Inc.（NASDAQ:OLMA - 免费报告）的股份增加了 1,714.9%</p>

<p>Franklin Resources Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 1,714.9% during the 4th quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund owned 273,706 shares of the company's stock after purchasing an additional 258,625 shares during the quarter. Franklin Resources Inc. owned about 0.48% of Olema Pharmaceuticals worth $1,596,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>富兰克林资源公司在最近向证券交易委员会提交的 13F 文件中披露，在第四季度其在 Olema Pharmaceuticals, Inc.（纳斯达克代码：OLMA - 免费报告）的股份增加了 1,714.9%。该基金在季度内购买了 258,625 股后，持有 273,706 股公司的股票。富兰克林资源公司在最近一个季度末持有 Olema Pharmaceuticals 约 0.48% 的股份，价值 1,596,000 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Olema Pharmaceuticals</strong> 警报：</p>
</div><p>A number of other institutional investors and hedge funds also recently made changes to their positions in OLMA. Wellington Management Group LLP raised its position in shares of Olema Pharmaceuticals by 52.1% in the fourth quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company's stock valued at $8,839,000 after purchasing an additional 522,799 shares during the period. Schroder Investment Management Group grew its stake in Olema Pharmaceuticals by 548.7% in the 4th quarter. Schroder Investment Management Group now owns 533,111 shares of the company's stock valued at $2,991,000 after buying an additional 450,924 shares during the last quarter. Pier Capital LLC bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $1,588,000. Pictet Asset Management Holding SA lifted its position in Olema Pharmaceuticals by 12.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,883,354 shares of the company's stock worth $10,980,000 after acquiring an additional 215,895 shares during the last quarter. Finally, JPMorgan Chase &amp; Co. boosted its holdings in shares of Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase &amp; Co. now owns 181,032 shares of the company's stock worth $2,162,000 after acquiring an additional 157,171 shares during the period. Institutional investors own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也对 OLMA 的持仓进行了调整。威灵顿管理集团在第四季度将其在 Olema Pharmaceuticals 的股份提高了 52.1%。威灵顿管理集团现在拥有 1,525,484 股公司的股票，价值 8,839,000 美元，在此期间又购买了 522,799 股。施罗德投资管理集团在第四季度将其在 Olema Pharmaceuticals 的股份增加了 548.7%。施罗德投资管理集团现在拥有 533,111 股公司的股票，价值 2,991,000 美元，在上个季度又购买了 450,924 股。Pier Capital LLC 在第四季度购买了 Olema Pharmaceuticals 的新股份，价值约 1,588,000 美元。Pictet 资产管理控股公司在第四季度将其在 Olema Pharmaceuticals 的股份提高了 12.9%。Pictet 资产管理控股公司现在拥有 1,883,354 股公司的股票，价值 10,980,000 美元，在上个季度又收购了 215,895 股。最后，摩根大通在第三季度将其在 Olema Pharmaceuticals 的持股增加了 658.7%。摩根大通现在拥有 181,032 股公司的股票，价值 2,162,000 美元，在此期间又收购了 157,171 股。机构投资者持有公司 91.78% 的股份。</p>
</div><h2>Olema Pharmaceuticals Stock Up 7.7 %</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票上涨 7.7%</h2>
</div><p>Shares of OLMA stock opened at $4.06 on Tuesday. The firm has a 50 day moving average of $4.30 and a 200-day moving average of $7.21. The company has a market cap of $277.43 million, a price-to-earnings ratio of -1.85 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62.</p>
<div class="lb-trans"><p>周二，OLMA 股票开盘价为 4.06 美元。该公司的 50 日移动平均价为 4.30 美元，200 日移动平均价为 7.21 美元。公司市值为 2.7743 亿美元，市盈率为-1.85，贝塔值为 2.10。Olema Pharmaceuticals, Inc.的 52 周最低价为 2.86 美元，最高价为 16.62 美元。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12. Analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）最近于 3 月 18 日（星期二）发布了季度财报。公司报告季度每股收益为（0.51 美元），超出市场共识预期的（0.63 美元）0.12 美元。分析师预计 Olema Pharmaceuticals, Inc.在本年度的每股收益将为-2.33 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have weighed in on the stock. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase &amp; Co. dropped their price target on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, March 28th. Finally, Oppenheimer reiterated an &#34;outperform&#34; rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.</p>
<div class="lb-trans"><p>几位分析师对该股票发表了看法。HC Wainwright 在 3 月 19 日（星期三）的研究报告中重申了对 Olema Pharmaceuticals 的 “买入” 评级，并设定了 30.00 美元的目标价。摩根大通在 3 月 28 日（星期五）的研究报告中将 Olema Pharmaceuticals 的目标价从 30.00 美元下调至 28.00 美元，并对该公司设定了 “增持” 评级。最后，Oppenheimer 在 3 月 19 日（星期三）的研究报告中重申了 “跑赢大盘” 评级，并将 Olema Pharmaceuticals 的目标价设定为 25.00 美元（低于 30.00 美元）。</p>
</div><p><strong>Read Our Latest Analysis on OLMA</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 OLMA 的最新分析</strong></p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症治疗的发现、开发和商业化。其主要产品候选药物为 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的第三阶段临床试验；同时 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的 1/2 期临床试验，并开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>Why NVIDIA Stock Could Soar Despite Wall Street Downgrades</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Olema Pharmaceuticals</li>
<li>3 只沃伦·巴菲特在波动时期必须购买的股票</li>
<li>尽管华尔街下调评级，为什么 NVIDIA 股票可能会飙升</li>
<li>万亿美元市值的意义超越数字</li>
<li>第一季度内部人士购买的三只大型股票：买入、卖出或持有</li>
<li>便士股票适合你的投资组合吗？</li>
<li>3 只热销新 IPO 逆势而上，抵御 2025 年市场下滑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OLMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 OLMA 吗？</strong> 访问 HoldingsChannel.com 获取 Olema Pharmaceuticals, Inc.（纳斯达克代码：OLMA - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OLMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Olema Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前...而 Olema Pharmaceuticals 并不在名单上。</p>
</div><p>While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Olema Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

富兰克林资源公司购入了 258,625 股 Olema Pharmaceuticals, Inc.（纳斯达克代码：OLMA）的股票